Vessi Medical brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC) utilizing bladder-specific cryotherapy technology.
Vessi Medical has raised $16.5M in total funding. The most recent round was Series A. The last funding was announced in February 2024.
Vessi Medical's investors include Israel Innovation Authority, Trendlines Group, ALIVE Israel HealthTech Fund, Agriline.
Vessi Medical is headquartered in Misgav, Israel.
Vessi Medical brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC) utilizing bladder-specific cryotherapy technology.
Vessi Medical is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vessi Medical — Funding & Investors." VCBacked, February 14, 2024, https://www.vcbacked.co/company/vessi-medical. Accessed September 30, 2026.
VCBacked. (2024). Vessi Medical — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/vessi-medical
{{cite web |title=Vessi Medical — Funding & Investors |url=https://www.vcbacked.co/company/vessi-medical |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated